摘要
目的 探讨槐耳颗粒联合分子靶向药物治疗脾虚型原发性肝癌(PHC)的临床疗效及对肝功能、免疫功能的影响。方法 回顾性分析2020年1月—2021年12月本院收治的PHC患者70例,按就诊先后顺序分为A组和B组各35例。两组患者均实施常规支持治疗。A组在常规治疗上使用分子靶向药物治疗,B组在A组的基础上联合槐耳颗粒治疗,两组患者皆进行4周的治疗。对两组治疗前后中医证候积分、生活质量、肝功能及免疫功能指标的变化实施观察,并评价两组临床疗效与安全性。结果 B组总有效率(97.14%)显著高于A组(80.00%)(P<0.05)。治疗前,两组中医症候积分比较,差异无统计学意义(P>0.05);两组中医症候积分在治疗后均降低,且B组积分低于A组(P<0.05);治疗前,两组患者的CD8^(+)、CD4^(+)和CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05);治疗后,两组患者的CD8^(+)、CD4^(+)水平较治疗前显著降低;B组CD4^(+)/CD8^(+)水平较治疗前提高,A组CD4^(+)/CD8^(+)水平较治疗前降低,且B组的CD8^(+)水平低于A组,CD4^(+)与CD4^(+)/CD8^(+)水平高于A组(P<0.05)。治疗前,两组的AST、ALT和TBIL水平比较,差异无统计学意义(P>0.05);治疗后两组AST、ALT和TBIL水平显著减少(P<0.05),且B组明显低于A组(P<0.05)。B组不良反应发生率(11.42%)高于A组(8.57%),但两组高血压、手足综合征、皮疹、恶心呕吐及腹泻等不良反应比较,差异无统计学意义(P>0.05)。治疗后两组生活质量均上升,且B组生活质量优于A组(P<0.05)。结论 槐耳颗粒联合分子靶向药物治疗PHC患者疗效确切,可减轻患者临床症状,改善患者的肝功能以及免疫功能指标,安全性较高,可在临床推广。
Objective To study the clinical effect of primary liver cancer(PHC) on liver function and immune function.Methods A retrospective analysis was performed on 70 patients with PHC admitted to our hospital from January 2020 to December 2021,who were divided into group A and group B with 35 cases each.Both groups received routine supportive treatment.Group A was treated with molecular targeted drugs on the basis of conventional treatment,and group B was treated with Huaier granule on the basis of group A.Both groups were treated for 4 weeks.The changes of TCM syndrome score,quality of life,liver function and immune function indexes before and after treatment were observed,and the clinical efficacy and safety of the two groups were evaluated.Results The total effective rate in group B was 97.14%,significantly higher than that in group A(80.00%)(P<0.05).The TCM syndrome scores of the two groups were decreased after treatment(P>0.05),and the scores of group B were lower than those of group A(P<0.05).Before treatment,the levels of CD8^(+),CD4^(+) and CD4^(+)/CD8^(+) were compared between 2 groups(P>0.05).After treatment,CD8^(+) and CD4^(+) levels in 2 groups were significantly lower than before treatment,CD4^(+)/CD8^(+) level in group B was higher than before treatment,CD4^(+)/CD8^(+) level was lower than before treatment,and CD8^(+) level in group B was lower than that in group A.The levels of CD4^(+) and CD4^(+)/CD8^(+) in group A were higher than those in group A(all P<0.05).Before treatment,the AST,ALT and TBIL levels of the two groups were compared(P>0.05),and the AST,ALT and TBIL levels of the two groups were significantly decreased after treatment(P<0.05).The levels of AST,ALT and TBIL in group B were significantly lower than those in group A after treatment(P<0.05).The incidence of ADR in group B(11.42%) higher than that in group A(8.57%),but the ADR of hypertension,hand-foot syndrome,rash,nausea,vomiting and diarrhea were compared between the two groups(P > 0.05).After treatment,the quality of life in both groups was increased(P<0.05).The quality of life of group B was better than that of group A(P<0.05).Conclusion The effect of locust ear granules combined with PHC patients can reduce clinical symptoms,improve liver function and immune function,and have high safety.
作者
石功亮
何勇
颜艳倩
SHI Gongliang;HE Yong;YAN Yanqian(Chenzhou First People′s Hospital,Chenzhou 423000,Hunan,China)
出处
《西部医学》
2024年第1期120-124,共5页
Medical Journal of West China
基金
郴州市技术创新引导项目(lcyl2021001)。
关键词
槐耳颗粒
分子靶向药物
脾虚型PHC
临床疗效
肝功能
免疫功能
Locust ear particles
Molecular targeted drugs
Spleen deficiency type PHC
Clinical efficacy
Liver function
Immune function
